AGE Centrum s.r.o.
- Address
- lock Available on a paid plan
Neurology and Psychiatry
The AGE Centrum s.r.o. site in Olomouc is conducting clinical research in nervous system diseases and mental disorders, with a strong focus on Alzheimer’s disease and related cognitive and behavioral symptoms. These studies are designed to evaluate new approaches for improving memory, thinking, function, and agitation control in people living with mild cognitive impairment, mild to moderate Alzheimer’s disease, and agitation associated with Alzheimer’s disease.
- Testing therapies aimed at improving cognition and daily function in early Alzheimer’s disease
- Evaluating treatments for agitation and behavioral symptoms linked to Alzheimer’s disease
- Studying options for people with biomarker evidence of inflammation in early neurodegenerative disease
Overall, this research area combines symptom management with efforts to slow or improve disease-related decline, offering potential benefit for both patients and caregivers.
Immunology and Skin Disease
Clinical trials at AGE Centrum s.r.o. also cover immune system diseases and skin and connective tissue diseases, especially atopic dermatitis. The studies are centered on reducing inflammation, improving skin symptoms, and maintaining treatment response over time in people with moderate-to-severe disease.
- Assessing long-term safety and effectiveness of new therapies for atopic dermatitis
- Comparing active treatment with placebo to better understand symptom control
- Exploring ways to maintain response after initial improvement in chronic skin inflammation
This research supports the development of better options for people whose skin disease remains difficult to control with standard care.
Rheumatology and Inflammatory Disease
The site is involved in musculoskeletal diseases research, with a clear emphasis on rheumatoid arthritis. These trials are focused on easing joint inflammation, improving disease activity, and finding more effective treatment strategies for people who have not responded well to prior therapies or who are newly diagnosed.
- Evaluating new anti-inflammatory treatments for moderate to severe rheumatoid arthritis
- Studying treatment combinations for early disease control in newly diagnosed patients
- Comparing investigational approaches with placebo or standard therapy to measure symptom improvement
By addressing both early and more established disease, this research aims to refine care for patients living with chronic inflammatory joint conditions.
Gastroenterology
Research at AGE Centrum s.r.o. includes digestive system diseases, particularly ulcerative colitis. The trial activity in this area is centered on achieving clinical remission and improving control of intestinal inflammation in people with active disease.
- Assessing whether treatment can help patients reach remission more effectively
- Measuring improvement in bowel symptoms and endoscopic signs of inflammation
- Supporting the search for better options for patients with persistent inflammatory bowel disease
This work reflects an ongoing effort to improve both symptom relief and disease control in chronic gastrointestinal inflammation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in AGE Centrum s.r.o.
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Multicenter, Randomized, Double blind, Placebo controlled Trial of the Safety and Efficacy of Flexible Doses of SEP 363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder. | Otsuka Pharmaceutical Development & Commercialization Inc. | Phase IV | Not Recruiting | Mar 2023 | Nov 2025 |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amlitelimab | 4 | Unknown | 2022-11-10 | 2024-10-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.